Chronic Refractory Cough Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Merck & Co, Kyorin Pharmaceuticals
DelveInsight’s ‘Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the United States, the EU-4 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Chronic Refractory Cough Overview
Cough is a reflex activity with elements of voluntary control. It forms part of the somatosensory system that involves visceral sensation, a reflex motor response, and associated behavioral responses. It is also a symptom of many common respiratory diseases, where it can be acute (less than 3 weeks duration), subacute (3–8 weeks duration), or chronic (more than 8 weeks duration). Chronic coughs last can be caused by gastroesophageal reflux disease, postnasal drip from sinus infections or allergies, or chronic lung conditions, such as asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and interstitial lung disease.
Chronic refractory cough is defined as a cough lasting more than 8 weeks that persists despite guidelines-based treatment, which may be treated by different medical specialties: Pulmonology, Allergy and Immunology, Digestive Health, and Otorhinolaryngology. CRC often occurs after a viral infection, and multiple factors contribute to CRC, which is divided according to the conditions affecting the upper and lower respiratory tracts. Often the etiology can be multifactorial, with more than one pathology present. Many causes may lead to the emergence of a chronic cough syndrome, the most frequent being pulmonary diseases (cancer, COPD, chronic bronchitis, bronchiectasis, asthma, pulmonary tuberculosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, and others). Certain factors like smoking, obesity, allergies, irritants in the home or work environment, and others increase the risk of CRC.
Chronic Refractory Cough Epidemiology Insights
-
A study conducted by Slovarp et al. (2018) mentioned that chronic cough was estimated to affect approximately 12% of the population. It was one of the most common complaints for patients seeking medical care. It accounted for over 20 million physician visits per year which significantly impacted the quality of life. In addition, about 3–7 million patients, i.e., 10–20% in the United States per year, had CRC.
-
Perotin et al. (2018) conducted a study that stated that the estimated prevalence was between 11% and 13% of the population in a recent meta-analysis of 90 studies. In this study, the prevalence of chronic cough was higher in several countries, while Europe accounted for approximately 12.7%. In another survey performed on about 1120 people with chronic cough, more than 70% of the subjects benefited from more than three consultations in connection with their chronic cough; however, a diagnosis was given in about only 53% of the cases, while 2.7–46% of chronic cough was represented as refractory in nature. Also, there were several risk factors associated due to chronic cough, where smoking contributed to be the major one.
Click here to learn more about the Chronic Refractory Cough Market Landscape
The Report Covers the Chronic Refractory Cough Epidemiology Segmented by:
-
Chronic Refractory Cough total prevalent cases
-
Chronic Refractory Cough total diagnosed cases
-
Chronic Refractory Cough total treatment cases
-
Chronic Refractory Cough total incident cases
Chronic Refractory Cough Market Outlook
Chronic Refractory Cough proves to be a huge burden on the patients who are fighting this debilitating condition. It is typically nonproductive, and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritating cough that may be localized to the laryngeal region. It significantly impairs patients’ quality of life. Unfortunately, in many situations, patients continue to experience Chronic Refractory Cough despite following the published guidelines for diagnosis and treatment. Currently, the market holds no approved therapy to treat Chronic Refractory Cough.
Key Companies Working in the Chronic Refractory Cough Market
-
Merck & Co
-
Kyorin Pharmaceuticals
-
NeRRe Therapeutics
-
Bellus Health
-
Shionogi
-
Axalbion
-
Aldeyra Therapeutics
And many others
Chronic Refractory Cough Therapies:
-
MK-7264
-
BLU-5937
-
S-600918
-
AX-8
-
Orvepitant Maleate
-
FP01
-
GDC-6599
And many others
Learn more about the Key Companies and Emerging Therapies in the Chronic Refractory Cough Market
Table of Contents
-
Key Insights
-
Chronic Refractory Cough Introduction
-
Executive Summary of Chronic Refractory Cough
-
Disease Background and Overview
-
Epidemiology and patient population
-
Chronic Refractory Cough Emerging Therapies
-
Chronic Refractory Cough Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Chronic Refractory Cough Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services